Dynavax Technologies is a biotechnology company focused on developing innovative immunotherapies to treat and prevent infectious diseases and cancer

Its research emphasizes harnessing the body's immune system to generate strong and durable responses, particularly through the use of its proprietary toll-like receptor (TLR) technology. The company is known for its commitment to advancing novel vaccine approaches and immune-modulating therapies, with a portfolio that includes products aimed at improving patient outcomes and enhancing immune response in various therapeutic areas. Dynavax collaborates with other organizations to drive advancements in biomedical research and bring transformative solutions to healthcare.